ResearchDx Appointment of New Chief Medical Officer to Meet NIH Push for Precision Medicine in Expediting Bench to Bedside" Strategies for Disease Treatment

Share Article

Life sciences firm ResearchDx has engaged Shelly Gunn MD, Ph.D., FCAP as Chief Medical Officer and Medical Director of Pacific Diagnostics to meet demand to increase speed at which new treatments reach patients.

Shelly Gunn, MD, Ph.D., FCAP

I'm delighted to join the ResearchDx team of top tier researchers and hope to add value to their advances in pharmaceutical development.

Internationally recognized as the "Contract Diagnostics Organization," ResearchDx specializes in the development of companion and in vitro diagnostics for the pharmaceutical, biotechnology, research, and diagnostic industries. To meet the demand for leveraging new technology and increase the speed at which new treatments reach patients, life sciences firm ResearchDx has appointed Shelly Gunn MD, PhD, FCAP as Chief Medical Officer and Medical Director of their CAP/CLIA certified clinical laboratory, Pacific Diagnostics.

Dr. Gunn's addition at ResearchDx and clinical laboratory, Pacific Diagnostics will expand the company's capabilities in the growing disciplines of Translational and Precision Medicine. Translational medicine aims to expedite the discovery of new diagnostic tools and treatments by using a multi-disciplinary, highly collaborative, "bench-to-bedside" approach. Precision medicine is an emerging approach for disease prevention and treatments individualized to variations in each person’s genes, environment, and lifestyle. https://www.nih.gov/precision-medicine-initiative-cohort-program.

The National Institutes of Health (NIH) has made a major push to fund translational and precision medicine, especially within biomedical research, with a focus on cross-functional collaborations (e.g., between researchers and clinicians); leveraging new technology and data analysis tools, and increasing the speed at which new treatments reach patients.

"I am delighted to be joining the globally recognized Contract Diagnostics Organization and look forward to working with the team in Irvine to promote continued excellence in the development of companion diagnostic assays for pharma, biotech, and the medical community. As Chief Medical Officer and Medical Director of our CAP/CLIA accredited laboratory, Pacific Diagnostics, I plan to rapidly translate new and innovative technologies from the research bench into clinically available patient testing for cancer, chronic disease, and wellness,” says Dr. Gunn.

A distinguished expert in molecular pathology, Dr. Gunn specializes in genomic biomarker identification for breast cancer and other solid tumors. Dr. Gunn’s Boards, Licensures, and Certifications include the American Board of Pathology, Certified in Clinical Pathology; Texas, New York, and California licensure, as well as a New York State Certificate of Qualification in Molecular and Cellular Tumor Markers.

For more information on the biopharma companion diagnostic test development process, translational, or precision medicine, please contact media representative Vicki Garcia at 619-660-6730.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Vicki Garcia
Research Dx
+1 619-660-6730
Email >
ResearchDx

Visit website